Most deep vein thromboses (DVTs) start in the calf, and most probably resolve
spontaneously. Thrombi that remain confined to the calf rarely cause leg symptoms or …

Venous thrombosis, including deep vein thrombosis (DVT) and pulmonary embolism (PE),
occurs at an annual incidence of about 1 per 1,000 adults. Rates increase sharply after …

Background The appropriate duration of oral anticoagulation after a first episode of venous
thromboembolism (VTE) is uncertain and depends upon VTE recurrence rates. Objective To …

Under normal circumstances, the coagulation system is balanced in favour of
anticoagulation.• Thrombin is the key effector enzyme of the clotting cascade.• Antagonists of …

This chapter about antithrombotic therapy for venous thromboembolic disease is part of the
seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …

Background In about a third of patients with venous thromboembolism, the cause of the
disorder is unexplained. In patients with atherosclerosis, activation of both platelets and …

We report a case of juvenile thrombophilia associated with a substitution of leucine for
arginine at position 338 (R338L) in the factor IX gene (factor IX–R338L). The level of the …

Objective.—To estimate ethnic-specific prevalence rates of factor V Leiden, an inherited
defect of hemostasis associated with risk of venous thrombosis. Design.—Survey of 4047 …

Background The recurrence rate after deep vein thrombosis (DVT) is high and the risk
factors for recurrent thromboembolic events have only been investigated on a small scale …

Background Standard therapy to prevent recurrent venous thromboembolism includes 3 to
12 months of treatment with full-dose warfarin with a target international normalized ratio …